Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0007095 (carcinoid)
 6,990 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We describe the case of a patient suffering from relapsing abdominal pain and vomiting over 4 years, in whom various radiological and endoscopic examinations remained normal. CT scan and MRI eventually showed a mesenteric mass corresponding to metastasis of an ileal carcinoid; this tumor was diagnosed only at laparotomy as well as his mesenteric and hepatic metastases. The different localization and clinical manifestations of carcinoid tumours as well as the difficulties of radiological diagnosis of tumours of the small bowel are mentioned; the diagnostic value of sonography. CT-scan and MRI in the diagnosis of hepatic metastasis is discussed.
 ...
PMID:[A difficult diagnosis]. 200 76

A case of primary carcinoid tumor of the seminal vesicles is presented. To our knowledge, this case documented by CT and MRI is unique in that it is the first described in this location. The tumor appears homogeneous and intensely enhanced after IV on CT, and hypointense on MRI on both T1- and T2-weighted images. On T2-weighted images, the tumor is heterogeneous.
 ...
PMID:Primary carcinoid tumor of the seminal vesicles: CT and MR findings. 206 Dec 73

The membranous labyrinth and 7th and 8th cranial nerves are well shown by magnetic resonance scanning but the lack of bone detail makes MRI secondary to CT for the investigation of lesions of the petrous temporal bone. Twenty-two intrinsic temporal bone tumours were examined by magnetic resonance in this study. Seven glomus tumours, one facial neuroma and one carcinoid tumor received intravenous gadolinium DTPA. All showed signal enhancement although the practical value of this enhancement was variable. The ability of MRI to demonstrate the jugular bulb separate from a glomus tumour confined to the middle ear, and signal enhancement of another middle ear tumour after partial removal are described, as well as the tissue characterization for discriminating between cholesteatoma and cholesterol granuloma for mass lesions in the petrous apex.
 ...
PMID:Magnetic resonance with gadolinium DTPA for the investigation of temporal bone tumours. 254 89

A case of carcinoid cardiopathy (C.C.) of the right heart, related to liver metastases secondary to a bronchial tumor, is reported. Non-invasive investigative methods have enabled an easy diagnosis of C.C.: liver metastases by scan and abdominal sonogram, restrictive myocardiopathy with typical tricuspid lesions by echocardiography and MRI, magnitude of the tricuspid regurgitation by cardiac Doppler. These extremely performing methods must allow an early diagnosis at a stage when the patient may be still operable, since C.C. is the most frequent cause of death in patients with carcinoid tumors.
 ...
PMID:[Carcinoid cardiopathy: value of ultrasonography and MRI. Apropos of a case related to bronchial tumor. Review of the literature]. 265 Jun 11

In parallel with the rapidly developing interest in the diastolic properties of ventricular function in the 1970s, the restrictive cardiomyopathies have taken their place as the third major category of primary heart muscle disease. The restrictive cardiomyopathies are characterized by primary abnormalities of diastolic ventricular function with normal to near normal systolic performance and little or no increase in end-diastolic or end-systolic dimensions of either right or left ventricle. The restrictive abnormality of ventricular function can result from myocardial or endomyocardial disease, the etiologies of which may be known or unknown. Diastolic dysfunction that is essentially myocardial can be idiopathic (probably an enzymatic/metabolic disturbance), infiltrative (myocardial interstitium), or within myocardial cells (storage diseases). Diastolic dysfunction that results from endomyocardial disease is typified by endomyocardial fibrosis or the hypereosinophilic syndrome, although carcinoid, metastatic malignancies, radiation, and anthracycline toxicity may be accompanied by endomyocardial restriction. Echocardiography and Doppler ultrasound, MRI, and radionuclear techniques have been major advances in providing diagnostic precision, contributing materially to the clinical identification of the restrictive cardiomyopathies as well as discriminating certain of their etiologies.
 ...
PMID:The restrictive cardiomyopathies. 306 85

Carcinoid tumor is regarded as a tumor with low grade malignancy, mostly originating from the gastrointestinal tract with little danger of metastasis. The authors encountered a very rare case of bronchial carcinoid tumor that had multiple metastasis to the intracranial space. The characteristics of radiological and hormonal examinations of this tumor are reported and discussed. The patient was a 73-year-old woman who gradually developed unsteadiness in walking and somnolence in daytime one month prior to admission. Those symptoms were aggravated and she began to vomit. On admission, neurological examination showed slight ataxia of left upper and lower extremities and dominant truncal ataxia. Chemical and hormonal examinations of blood and urine showed, gastrin was 230 pg/ml (37-172), ACTH was 67 pg/ml (< 60), serotonin was 565 ng/ml (53-200), and urinary 5-HIAA was 9.9 mg/day (0.8-4.8). Tumor markers (CEA, AFP, HGG, NSE) were all negative. Radiological examinations (chest X-P, CT scan) of her lung demonstrated a 3 x 3 cm tumor mass adjacent to the hilum of the left lower lobe. CT-scan of the head demonstrated cystic tumor in the vermis of the cerebellum (3 x 3 cm), the right posterior parietal lobe and the right temporal lobe. The wall of each tumor was enhanced by contrast medium. T1 weighted MRI demonstrated the walls of cystic tumors as iso intensity and the contents as low and high intensity with niveau formation. Little edema was recognized around the tumors. The wall of each cystic tumor was enhanced by Gd-DTPA.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Bronchial carcinoid tumor with multiple brain metastasis]. 816 99

Recently radiolabeled somatostatin analog, [111In]pentetreotide, was developed and its usefulness for the diagnosis and localization of neuroendocrine tumors has been described. In this paper, we reported the results of [111In]pentetreotide scintigraphy in four patients with gastroenteropancreatic endocrine tumors. Two patients with metastatic gastrinoma, one patient with gastric carcinoid, and one patient suspected with gastrinoma, were injected with 119-156 MBq of [111In]pentetreotide. Planar and SPECT images were obtained 4, 24, and 48 hours postinjection. Both primary and metastatic tumors were well visualized in patients with metastatic gastrinoma. Especially in one patient small liver metastases which were not detected by CT or MRI were imaged. We could not obtain positive images in the other two patients. Four-hour or 24-hr images were better than 48-hr images because of higher count density and lower gut activity. No significant adverse effect were seen in any patient. [111In]pentetreotide scintigraphy is a useful procedure for the localization of gastroenteropancreatic endocrine tumors.
 ...
PMID:[Imaging of somatostatin receptor using 111In-pentetreotide]. 868 86

We present a case of metastatic carcinoid tumor metastatic to the heart, presenting as ventricular arrhythmia and diagnosed by 111Inpentetreotide scintiscan despite negative endocardial biopsy. The incidence and diagnosis of carcinoid heart disease is discussed, as well as the complementary role of high-resolution anatomical images (CT, MRI) with functional images (SPECT, PET) to determine the correct diagnosis of this rare condition.
 ...
PMID:Visualization of myocardial metastasis of carcinoid tumor by indium-111-pentetreotide. 879 Feb 10

Neuroendocrine gut and pancreatic tumours have provided a diagnostic and therapeutic challenge over the years. These rather slowly growing neoplasms have been assigned a good prognosis but when liver metastases are present the prognosis is not better than that of most other malignant tumours. Despite the development of improved diagnostic procedures many patients are still referred at a stage of the disease too late for surgical cure, at which time medical treatment is warranted. The diagnosis is based on histopathological diagnosis including silver stainings (Grimelius, Masson) and immunohistochemistry for chromogranin A and synaptophysin. Analysis of chromogranin A in the plasma is an important adjunct in the screening for various types of neuroendocrine gut and pancreatic tumours. About 80%-100% of patients with verified neuroendocrine gastrointestinal tumours have elevated circulating levels of this glycoprotein. Depending on clinical symptoms the chromogranin A analysis is supplemented by other peptide hormone analyses as well as urinary 5-HIAA for patients with midgut carcinoid tumours. In the past the localization procedures were based on CT, MRI and ultrasound investigations but in recent years somatostatin receptor scintigraphy (octreoscan) and endoscopic ultrasonography have significantly improved the diagnostic potential. Almost 80% of neuroendocrine gastrointestinal tumours present somatostatin receptor subtype 2 binding 111Indium-labelled octreotide which can be used for staging of the disease, and which also indicates whether or not somatostatin analogues can be used in the treatment of these tumours. Surgery is still a cornerstone in the treatment of neuroendocrine gastrointestinal tumours, even if the patients are beyond cure. Debulking procedures and bypassing operations are important for improving clinical condition and facilitating impending medical treatment, and during the past decade a more aggressive surgical approach has emerged. The medical treatment is based on chemotherapy, and the use of somatostatin analogues and alpha-interferons. Chemotherapy, in particular the combination of streptozotocin with 5-FU or doxorubicin, is still first-line treatment for most endocrine pancreatic tumours, while somatostatin analogues and alpha-interferons are considered first-line for classical midgut carcinoids. Chemotherapy and biotherapy can be combined in many patients, and changes from one medical treatment to another during the course of the disease is mandatory for control of the disease. It is important to realise that most patients with malignant tumours are not cured by medical treatment but that the disease can be controlled for extended periods of time. In the future it will be possible to individualize treatments on the basis of new information about such features of tumour biology as proliferation capacity, expression of adhesion molecules, and growth factors and their receptors.
 ...
PMID:Neuroendocrine gastrointestinal tumours. 883 99

This study demonstrates the appearance of small bowel tumors on MR images. Sixteen patients with tumors involving small bowel were studied by MRI. All tumors were proven with histopathology. Eleven patients had primary tumors of the small bowel, which included the following: four carcinoid tumors, three adenocarcinomas, two lymphomas, one leiomyosarcoma, and one leiomyoma. Five patients had recurrent or metastatic disease to small bowel: two patients had colon cancer, one patient had pancreatic cancer, one patient had uterine leiomyosarcoma, and one patient had chloroma (leukemia). MR examination included breath-hold T1-weighted spoiled gradient echo (all patients), immediate postgadolinium-spoiled gradient echo (10 patients), and 2 to 4 minutes postgadolinium T1-weighted, fat-suppressed images (all patients). Tumor size, local extent, signal intensity, and enhancement features of tumor and adjacent tissue were determined. Tumor ranged in diameter from 1 to 9 cm (mean, 4.0 cm). Tumors had similar signal intensity to normal small bowel on precontrast images. Fourteen malignant tumors showed heterogeneous enhancement greater than adjacent bowel on gadolinium-enhanced images. Tumor local extent was best shown on precontrast-spoiled gradient-echo images and postgadolinium T1-weighted fat-suppressed images. Image quality was most consistent on breath-hold images. The results of this study show that small bowel tumors are demonstrable on MR images. Precontrast breath-hold T1-weighted spoiled gradient-echo images and gadolinium-enhanced fat suppressed images demonstrate tumor extent most reliably.
 ...
PMID:Small bowel neoplastic disease: demonstration by MRI. 895 28


1 2 3 4 5 6 7 8 9 10 Next >>